FABIANA AGENA

(Fonte: Lattes)
Índice h a partir de 2011
13
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • article 88 Citação(ões) na Scopus
    Recurrence of FSGS after Kidney Transplantation in Adults
    (2020) UFFING, Audrey; PEREZ-SAEZ, Maria Jose; MAZZALI, Marilda; MANFRO, Roberto C.; BAUER, Andrea Carla; DRUMOND, Frederico de Sottomaior; O'SHAUGHNESSY, Michelle M.; CHENG, Xingxing S.; CHIN, Kuo-Kai; VENTURA, Carlucci G.; AGENA, Fabiana; DAVID-NETO, Elias; MANSUR, Juliana B.; KIRSZTAJN, Gianna Mastroianni; JR, Helio Tedesco-Silva; V, Gilberto M. Neto; ARIAS-CABRALES, Carlos; BUXEDA, Anna; BUGNAZET, Mathilde; JOUVE, Thomas; MALVEZZI, Paolo; AKALIN, Enver; ALANI, Omar; AGRAWAL, Nikhil; MANNA, Gaetano La; COMAI, Giorgia; BINI, Claudia; MUHSIN, Saif A.; RIELLA, Miguel Carlos; HOKAZONO, Silvia R.; FAROUK, Samira S.; HAVERLY, Meredith; MOTHI, Suraj Sarvode; BERGER, Stefan P.; CRAVEDI, Paolo; V, Leonardo Riella
    Background and objectivesFSGS recurrence after kidney transplantation is a major risk factor for graft loss. However, the natural history, clinical predictors, and response to treatment remain unclear because of small sample sizes and poor generalizability of single-center studies, and disease misclassification in registry-based studies. We therefore aimed to determine the incidence, predictors, and treatment response of recurrent FSGS in a large cohort of kidney transplant recipients.Design, setting, participants, & measurementsThe Post-Transplant Glomerular Disease (TANGO) project is an observational, multicenter, international cohort study that aims to investigate glomerular disease recurrence post-transplantation. Transplant recipients were screened for the diagnosis of idiopathic FSGS between 2005 and 2015 and details were recorded about the transplant, clinical outcomes, treatments, and other risk factors.ResultsAmong 11,742 kidney transplant recipients screened for FSGS, 176 had a diagnosis of idiopathic FSGS and were included. FSGS recurred in 57 patients (32%; 95% confidence interval [95% CI], 25% to 39%) and 39% of them lost their graft over a median of 5 (interquartile range, 3.0?8.1) years. Multivariable Cox regression revealed a higher risk for recurrence with older age at native kidney disease onset (hazard ratio [HR], 1.37 per decade; 95% CI, 1.09 to 1.56). Other predictors were white race (HR, 2.14; 95% CI, 1.08 to 4.22), body mass index at transplant (HR, 0.89 per kg/m(2); 95% CI, 0.83 to 0.95), and native kidney nephrectomies (HR, 2.76; 95% CI, 1.16 to 6.57). Plasmapheresis and rituximab were the most frequent treatments (81%). Partial or complete remission occurred in 57% of patients and was associated with better graft survival.ConclusionsIdiopathic FSGS recurs post-transplant in one third of cases and is associated with a five-fold higher risk of graft loss. Response to treatment is associated with significantly better outcomes but is achieved in only half of the cases.
  • article 2 Citação(ões) na Scopus
    Awareness of Inadvertent Use of Yellow Fever Vaccine Among Recipients of Renal Transplant
    (2020) MIRANDA, Lara Judith Cabral; AGENA, Fabiana; SARTORI, Ana Marli Christovam; DAVID-NETO, Elias; AZEVEDO, Luiz Sergio; PIERROTTI, Ligia Camera